Month: March 2025

New York Mortgage Trust Declares First Quarter 2025 Common Stock Dividend of $0.20 Per Share, and Preferred Stock Dividends

Written by Customer Service on March 20, 2025. Posted in Dividend Reports And Estimates.

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.20 per share on shares of its common stock for the quarter ending March 31, 2025. The dividend will be payable on April 28, 2025 to common stockholders of record as of the close of business on March 31, 2025. In addition, the Board declared cash dividends on the Company’s 8.000% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series D Preferred Stock”), 7.875% Series E Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series E Preferred Stock”), 6.875% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series F Preferred Stock”) and 7.000% Series G Cumulative Redeemable...

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer Advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030 Discontinuing further internal clinical development of vobra duo; exploring potential partnering Cash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026 Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of...

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines. “Throughout 2024, we shared multiple data updates from our two lead anti-cancer medicines, NUC-7738 and NUC-3373,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer....

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2024. “Since our founding, Vaxart has been on a mission to transform global health with the goal of pioneering oral pill vaccines that can provide protection against common viral diseases safely and effectively,” said Steven Lo,...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 Proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2024 operating and financial results and reviewed recent business...

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026 TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction (“HFrEF”) in March 2025 Cash and cash equivalents of $141.2 million as of December 31, 2024 and February 2025 private placement gross proceeds of approximately $185.0 million, together expected to provide a cash runway into Q4’28WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”),...

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “With initial data from the clinical trial of SENTI-202, we are getting a glimpse into the potential profile...

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2024. “In 2024, we prepared our RAS-targeting franchise to enter the...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed Phase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy data Cash runway projected through at least Q1 2027SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024, along with key accomplishments and upcoming milestones. “Skye’s...

Oxbridge Re Announces 2024 Fourth Quarter Results on March 26, 2025

Written by Customer Service on March 20, 2025. Posted in Public Companies.

GRAND CAYMAN, Cayman Islands, March 20, 2025 (GLOBE NEWSWIRE) — Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty today, announced that it plans to hold a conference call on Wednesday March 26, 2025 at 4:30 p.m. Eastern Time to discuss results for the fourth quarter and year ending December 31, 2024. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge Re’s management will host the conference call, followed by a question and answer period. Interested parties can listen to the live presentation by dialing the listen-only number below.Date:...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals